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Abstract
Introduction High glucose concentrations induce the
production of IL-1β in human pancreatic beta cells
leading to impaired insulin secretion, decreased cell
proliferation and apoptosis. Blockade of IL-1 signalling
with the recombinant human IL-1 receptor antagonist
anakinra reduces HbA1c in patients with type 2 diabetes.
The aims of the present study were to identify: (1) candidate
surrogates for improved glycemia in type 2 diabetic
patients following treatment with anakinra, (2) proteins
that change serum concentration because of anakinra
treatment and (3) candidate biomarkers that may predict
improved glycemia in type 2 diabetic subjects treated
with anakinra.
Methods Surface-enhanced laser desorption/ionisation
time-of-flight mass spectrometry was used to analyse
serum from 67 type 2 diabetic patients who had received
either placebo or anakinra for 13 weeks. Immunodeple-
tion with magnetic protein G bead-coupled antibodies
were used to identify three proteins and Western blotting
confirmed the biomarker concentration pattern of four
proteins.
Results Twelve proteins, including transthyretin (TTR) and
transferrin (Tf), were identified as candidate surrogates for
improved glycemia. Six proteins, including retinol-binding
protein 4 (RPB4) and a protein tentatively identified as
modified apolipoprotein-A1 (apo-AI), increased expression
as a consequence of anakinra treatment and four proteins
were candidate biomarkers that may predict improved
glycemia following anakinra treatment. Furthermore, we
found increased RBP4 to be associated with improved beta
cell secretory function and increased TTR, RBP4 and
modified apo-AI (peak at 28,601 Da) to be associated with
decreased inflammation.
Conclusions Anakinra-induced changes in the serum
proteome pool associated with a decreased cardiovascular
disease risk, reduced inflammation and improved beta
cell secretory function.
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Introduction
IL-1β is a proinflammatory cytokine that has been implicated
as an effector molecule of inflammatory beta cell destruction
leading to type 1 diabetes [1]. Intra-islet production of IL-1β
may also play a role in the pathogenesis of type 2 diabetes
[2]. In pancreatic sections obtained from type 2 diabetic
patients, beta cells express IL-1β [3]. High glucose levels
increase beta cell production and release of IL-1β via
reactive oxygen-dependent activation of the inflammasome
[4], leading to impaired insulin secretion, decreased cell
proliferation and apoptosis in human islets in vitro [3].
IL-1-receptor antagonist (IL-1Ra) is a naturally occurring
competitive inhibitor of IL-1 binding to the IL-1 receptor. IL-
1Ra protects human beta cells from glucose-induced
functional impairment and apoptosis [3]. The expression
of IL-1Ra is reduced in pancreatic islets in patients with
type 2 diabetes [5]. Blockade of IL-1R with the recombi-
nant human IL-1Ra anakinra reduced HbA1c, enhanced C-
peptide secretion, reduced the proinsulin to insulin ratio
and reduced the levels of IL-6 and C-reactive protein
(CRP) in type 2 diabetic patients [2]. Insulin resistance,
insulin-regulated gene expression in skeletal muscle,
serum adipokine levels and body mass index (BMI) did
not change during treatment with anakinra [2, 6].
Genetically determined low baseline IL-1Ra, body
weight and BMI have been identified as predictors of
improved glycemia following anakinra treatment [2, 7].
Body weight and BMI were interpreted as surrogates for
drug distribution volume, suggesting that higher systemic
drug concentrations predict a glycemic response. Neither
baseline nor changes in levels of CRP or IL-6 were
correlated with changes in HbA1c. Because not every
patient responded to the same extent to the treatment, it is
important to investigate if there are other predictors for the
glycemic response of the individual type 2 diabetic patients
to IL-1 antagonism. Our aims were therefore: (1) to find
candidate surrogates for improved glycemia in type 2
diabetic patients treated with anakinra, (2) to find proteins
that change serum concentration as a consequence of
anakinra treatment and (3) to find more precise or useful
biomarkers that may predict improved glycemia in type 2
diabetic patients treated with anakinra.
For this purpose, we analysed sera from the described
study [2] by surface-enhanced laser desorption/ionisation
time-of-flight mass spectrometry (SELDI-TOF-MS) which
separates proteins and peptides according to their mass-to-
charge ratio. SELDI-TOF-MS provides a sensitive and
reproducible method to detect and resolve multiple proteins
bound to protein chip arrays. The platform has been used in
several large-scale proteomic clinical studies on plasma,
serum, cerebrospinal fluid and urine [8–11]. It has further
been used as a tool in the development of diagnostic assays
of various diseases, including several types of cancer, heart
infarction, Alzheimer’s disease, rheumatoid arthritis and
chronic alcoholism [9, 12–18].
Methods
Patients Patient samples originate from a placebo-
controlled, double-blind, parallel-group study involving 70
individuals with type 2 diabetes at two centres (31 patients
in Denmark and 39 patients in Switzerland) [2]. Patients
received either once-daily recombinant human IL-1Ra
(100 mg of anakinra) or placebo by subcutaneous self-
administration for 13 weeks. Baseline and 13th week sera
from all 67 patients who completed the primary study were
analysed in this study. Sera were stored at −80°C until and
had been thawed three times prior to analysis.
Study Design The patients were divided as follows: (1)
anakinra responders (n=21), (2) anakinra non-responders
(n=13), (3) placebo “responders” (n=10) and (4) placebo
“non-responders” (n=23). Response was defined as any
reduction in HbA1c following 13 weeks of intervention.
The number of responders was 21 of 34 patients in the
anakinra group and 11 of 33 in the placebo group [2].
Glycosylated haemoglobin A1c (HbA1c) is the fraction of
the normal and abundant haemoglobin A variant which is
irreversibly and non-enzymatically glycosylated by exposure
to glucose in plasma. The rationale for using HbA1c as
primary endpoint in the anakinra in type 2 diabetes trial was
that HbA1c correlates well with average plasma glucose and
thus reflects the ambient mean plasma glucose concentration
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over the past 4–12 weeks with a major contribution from the
first 4-week period [19]. This endpoint was therefore well
suited to investigate the effect of anakinra on metabolic
control after 4 and 13 weeks of therapy, whereas acute
(<1 week) effects on metabolic control were studied by the
means of home monitoring of fasting blood glucose.
To identify candidate surrogate biomarkers for improved
glycemia, we compared the spectra at baseline with spectra at
13 weeks of treatment in group 1. To control for differences
that were unrelated to the primary clinical outcome, the same
comparison was done in group 2. Only peaks that were
significant in group 1 were carried forward. To control for
the placebo effect, the same comparison was done in the
placebo groups. To identify changes in the proteome pool
from baseline to 13th week as a consequence of anakinra
treatment, we sought spectrum differences between baseline
and 13 weeks of treatment in all anakinra-treated patients
(groups 1 and 2). To exclude the placebo effect, we ensured
that the same differences were not found in the placebo
groups (groups 3 and 4). The protein changes due only to
anakinra treatment were those significant only in the
anakinra group. Protein changes also significant as surrogates
for outcome were deleted. To identify biomarkers that may
predict improved glycemia in type 2 diabetic patients treated
with anakinra, we looked for spectrum differences between
groups 1 and 2 at baseline. To eliminate the placebo effect,
we ensured that the same differences were not found
between groups 3 and 4. Biomarkers that may predict
improved glycemia to the treatment were those unique for
group 1.
Albumin Depletion and SELDI-TOF-MS Analysis All
patient serum samples were depleted in a high throughput
automated system. The eluate from the depletion step for
each patient was analysed using five different array
conditions: CM10 pH 7, Q10 pH 5, Q10 pH 9, H50 and
IMAC30-Nickel. Arrays were prepared using an automated
system and read in a PCS-4000 instrument (Bio-Rad) with
two laser settings. A high laser setting focused on larger
proteins (4,000–100,000 Da) while a low setting was
employed for peptides (2,000–10,000 Da). For each patient,
a single biological replicate was albumin depleted and
analysed in duplicate by SELDI-TOF-MS. Mass values in
this study are assumed to have a single charge and therefore
are reported as Da. Detailed protocols for albumin
depletion, array preparation and array reading are included
as supplementary information.
Identification of Proteins with Protein G Beads Albumin-
depleted human reference serum was produced using blue
trisacryl resin and diluted in Tris-Buffered Saline Tween-20
(TBST). Protein G beads (Invitrogen) were added to
different Eppendorf tubes and washed in phosphate-
buffered saline (PBS). Anti-transthyretin (TTR), anti-
retinol binding protein 4 (RPB4) and anti-transferrin (Tf)
antibodies (DakoCytomation, Glostrup, Denmark) were
diluted in PBS, added to the tubes and shaken for 30 min
at room temperature. The beads were washed three times in
TBST and incubated with diluted albumin-depleted serum
for 30 min with shaking. The unbound sample was
analysed on SELDI arrays using the specified protocol. A
control was made using the same protocol but without
antibody.
Quantitative Western Blotting Sera from the patients with
the highest, an intermediate and the lowest peak amplitude
of TTR, RBP4, Tf and 28,601 Da protein (to which we
assigned the preliminary identity of modified apolipoprotein-
AI (apo-AI)) were diluted in TBST (TTR, apo-AI and Tf) or
water (RBP4) and heated for 5 min at 80°C. Molecular weight
markers (Bench Marker and Magic Marker (Invitrogen)) and
diluted sera mixed with loading buffer were electrophoresed
on 10% Bis-Tris SDS-PAGE gels (Invitrogen) and transferred
to nitrocellulose membranes (Invitrogen). Western blotting
was performed with non-fat milk (Merck) as a blocking agent.
Blots were incubated overnight at 4°C with primary antibody
(anti-TTR, anti-RBP4, anti-apo-AI or anti-Tf) and for 1 h at
room temperature with polyclonal anti-Rabbit IgG (Cell
Signalling, Danvers, MA, USA). The membranes were placed
for approximately 5 min in developing agent (LumiGlo
reagent, Cell Signaling, Danvers, MA). Chemiluminescence
was used as the output signal. Imaging of the membranes was
performed using a LAS-3000 Image Reader (Fuji Film,
Tokyo, Japan).
Statistical Analyses The software R version 2.7.0 (see
www.r-project.org) was used for the statistical analysis. A
Wilcoxon signed-rank test (significance level of p<0.05)
was used to test for differences in protein levels to identify
biomarkers as surrogates for improved glycemia, to identify
changes in the proteome pool from baseline to 13 week as a
consequence of anakinra treatment and to test for significant
changes in clinical markers. To identify biomarkers that
may predict improved glycemia in patients treated with
anakinra, both a Mann–Whitney test and an estimation of
the area under the receiver operator characteristic curve
(AUC) with significance levels of p<0.05 and AUC>
0.69, respectively, were employed.
CiphergenExpress Data Manager was used to find and
label protein peaks. To confirm that all peaks were labelled
correctly, the peaks representing candidate biomarkers were
manually relabelled and the statistical tests (Wilcoxon and
Mann–Whitney) were repeated. Some of the peaks were
represented in more than one SELDI array condition; only
one of them was saved for further analysis. If the peak was
represented in both the “high mass” and the “low mass”
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reading protocols, the peak in the “high mass” reading
protocol was retained. If the peak was represented in
different SELDI array conditions, the peak in the condition
with best CV value was retained.
A correlation test was performed on all the remaining
peaks where r>0.7 was considered significant as a
reasonable compromise between stringency and sensitivity.
Peaks that were strongly correlated and had Da values that
were either twice or half the value of each other were
considered to be either a dimer or a double charge of the
protein. Only the monomer, the whole protein, was kept for
further analysis. Other peaks that were strongly correlated
were considered to be different modifications of the same
protein. A correlation test where p<0.05 vas considered
significant was also used to test for correlation between
changes in serum protein concentration and changes in
clinical markers.
Resampling of the results was performed in R using a
permutation test with a significance level of p<0.05 was
performed on the remaining peaks. Only peaks that were
considered significant after resampling were kept for further
analysis.
Results
SELDI Analysis Analysis of the 134 samples run in
duplicate produced 539 peak clusters. When the protein
peak intensities were compared between the groups, 148
of them showed significantly different serum levels in at
least one of the three tests: 49 potentially useful as
surrogates for improved glycemia, 76 that changed
expression because of treatment with anakinra and 23
that may predict glycemic response to the treatment.
After peak alignment, resampling and deletion of peaks
present in more than one condition the following
numbers of candidate biomarkers were found: 12 potentially
useful as surrogates for improved glycemia (Table 1), six that
changed expression because of treatment with anakinra
(Table 2) and four that may predict glycemic response to
the treatment (Table 3 and 4).
A correlation test showed the following protein peaks to
be highly correlated to one another: 7,048, 14,089, 14,300,
14,507 and 27,788 Da (r=0.7–0.8); 13,944, 14,300 and
27,788 Da (r=0.7–0.8); 39,866 and 79,628 (r=0.83;
Table 1) and 21,086 and 21,278 Da (r=0.72; Table 2),
respectively. A strong correlation is an indication that the
peaks are biochemically related and could represent
modifications with the same expression pattern or species
created in the ionisation process (e.g., dimers or multiply
charged peaks) that appear at different mass readings but
represent the same protein [20].
Identification of Proteins with Protein G Beads In this type
of proteomics study emphasis is placed on analysing whole
proteins from individual patients. The protein peaks that
were investigated were chosen based on the fact that they
were judged to be high quality peaks in our data set. Their
identities were not known ahead of time but the peaks at
13,752, 21,086, 28,601 and 79,628 had masses very close
to those of TTR, RBP4, apo-AI and Tf, respectively. We
therefore assigned these preliminary identities to the
proteins. Depletion with magnetic protein G beads and
specific antibodies confirmed the identities of TTR, RBP4
and Tf (Fig. 1). The antibodies against apo-AI did not
deplete the large peak at 28,100 Da or the shoulder at
28,601 Da that are visible in the upper spectrum of Fig. 1c,
which depicts depletion of the peak at 27,788 Da by the
anti-TTR antibody.
Western Blotting Western blotting verified the concentration
patterns of TTR, RPB4, ApoA1 and Tf found in the SELDI-
TOF-MS analysis. For each biomarker, we analysed three
different patient samples: a serum with the lowest peak
amplitude, one with intermediate peak amplitude and one
with the highest peak amplitude of the respective
proteins. The patient with the lowest peak amplitude
had the lowest concentration quantified by Western
blotting and the patient with the highest peak amplitude
had the highest concentration (Fig. 2).
Correlation with Clinical Parameters In group 1 and 2,
changes in RBP4 were negatively correlated to IL-6, CRP
and stimulated insulin levels and positively correlated to
plasma glucose after 120 min during OGTT and fasting
insulin levels. Changes in the 28,601 Da protein were
negatively correlated to IL-6 and CRP. The 7,042 Da
protein was positively correlated to free fatty acids (FFA)
and negatively correlated to CRP, the 8,208 Da protein
was positively correlated to TG and cholesterol and the
20,990 Da protein was negatively correlated to IL-6 and
CRP. In group 1, changes in TTR were negatively
correlated with IL-6 and CRP, changes in the 2,740 Da
protein were positively correlated to fasting insulin and
negatively correlated to IL-6, changes in the 39,866 Da
protein were positively correlated to stimulated C-peptide
and the 56,878 Da protein was negatively correlated to
CRP, IL-6 and positive correlated to fasting insulin
levels. In group 1 baseline. the 5,898 Da protein was
positively correlated to high-density lipoprotein (HDL)
and CRP and negatively correlated to FFA, the 8,741 Da
protein was positively correlated to TG and FFA and the
50,123 Da protein was negatively correlated to LDL, TG,
cholesterol and BG. None of the changes in peak
amplitude were significantly correlated to HbA1c or
fasting C-peptide (Table 4).
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Discussion
If all samples are treated identically, SELDI-TOF-MS is
reproducible and quantitative. The method has been used
successfully in large-scale proteomic studies of biomaterial
from individual patients [8–10, 14, 17]. The reproducibility
of SELDI-TOF-MS analysis, however, is sensitive to
sample preparation and analytical conditions, which can
have a significant impact on protein peak detection [20,
21]. Sample collection protocols can be flexible with
regard to clotting times, transport and storage time on ice
and up to three freeze/thaw cycles do not change the
protein profile significantly as long as the samples are
thawed on ice [20, 21]. The critical issue is that all
individual samples are treated in exactly the same way
[20]. We carefully treated all the samples including
controls (human reference serum) in a highly standardised
way. All samples had been through three freeze/thaw
cycles before SELDI analysis, were stored at −80°C and
thawed on ice. We obtained reproducibility with an
average CV of 13% for Q10 pH5, which was the surface
condition with the highest number of significant peaks.
One of the limitations in using SELDI-TOF-MS is the
time-consuming and complicated process of identification
of the significant peaks. SELDI-TOF-MS cannot sequence
peptides and, therefore, is a poor platform for protein
identification. To identify proteins, they must be purified,
checked by SELDI using the same array surface on which it
was originally identified and sequenced on another type of
mass spectrometer. A more direct route to identification is
through the specificity of antibodies. This method does not
require other mass spectrometers but does necessitate
knowledge of the identity of common SELDI-TOF-MS
peaks. The identities of TTR, RBP4 and Tf were confirmed
by immunodepletion of the respective proteins with
magnetic protein G bead-coupled antibodies. When we
compared the peak intensities of TTR, RBP4, ApoA1 and
Tf with the intensities of the bands on Western blots, we
Table 2 Proteins altering concentration due to anakinra treatment
Peak (Da) Protein identity Biomarker change
at 13 weeks
P value for treateda
(n=34, Wilcoxon)
p value for treateda
(n=34, permutation test)
7,042 Unknown Up 0.050 0.025
8,208 Unknown Up 0.025 0.013
20,990 Unknown Up 0.009 0.005
21,086 RBP4 Up 0.017 0.009
21,278 RPB4 (modified) Up 0.043 0.021
28,601 Apo-A1b (modified) Up 0.007 0.004
a The treated patients received daily subcutaneous injections with 100 mg of anakinra for 13 weeks
b The final identity of the 28,601 Da protein as being modified apo-AI has not been definitively established; the preliminary identity is based on the mass
and similarity to Western blot findings
Table 1 Biomarkers potentially useful as surrogates for clinical outcome
Peak (Da) Protein identity Biomarker change at 13 weeks p value for respondera
(n=21, Wilcoxon)
p value for respondera
(n=21, permutation test)
2,740 Unknown Up 0.016 0.009
7,048 Unknown Up 0.022 0.011
13,752 Transthyretin Up 0.002 0.001
13,944 Transthyretin (modified) Up 0.006 0.004
14,089 Transthyretin (modified) Up 0.004 0.003
14,300 Transthyretin (modified) Up 0.001 0.001
14,507 Transthyretin (modified) Up 0.001 0.001
14,758 Transthyretin (modified) Up <0.001 0.001
27,788 Transthyretin (dimer) Up 0.013 0.007
39,866 Unknown Up 0.042 0.021
56,878 Unknown Up 0.004 0.003
79,628 Transferrin Up 0.042 0.021
a Response was defined as any reduction in HbA1c during the 13 week of intervention
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found the same patterns, but not the same fold increase
between patients as we found in SELDI analysis. We
therefore investigated the effect on the four different peak
intensities of diluting the albumin-depleted serum two-fold.
We found that there was a linear correlation between the
peak intensity and the albumin-depleted serum concentration,
but the fold increase in peak intensity did not correspond to the
fold increase in amount of protein loaded. This supported the
Western blot findings.
We found a significant increase in the serum level of
TTR in the anakinra responder group and TTR is therefore a
candidate biomarker as surrogate for clinical outcome. As type
2 as well as type 1 diabetic patients have been found to have a
decreased level of TTR compared to healthy controls [22–24],
an increase in TTR might be a marker of improved metabolic
control, although there was no statistical correlation between
TTR and glycemic markers. Because reduced levels of TTR
have been associated with inflammation [25–27] the rise in
TTR might also signal decreased inflammation and we
confirm that an increase in serum TTR is negatively
correlated to IL-6 and CRP. However, although anakinra
markedly reduced serum CRP and IL-6, these inflammatory
markers were not correlated to clinical outcome [2, 7].
The level of RBP4 increased when type 2 diabetic
patients were treated with anakinra. Plasma RBP4 is
reduced in rats with spontaneous onset of type 1 diabetes
[28], rats with streptozotocin-induced diabetes [29] and
humans with new-onset type 1 diabetes, but the levels
Δ peak intensity (Da) Significant correlations (p<0.05)
Significant correlations in changes from baseline to 13 weeks
2,740 Δ IL-6, Δ fasting insulin
7,048 Δ CRP
13,752 Δ IL-6, Δ CRP
13,944 Δ CRP
14,089 Δ IL-6, Δ CRP, Δ fasting insulin
14,300 Δ IL-6, Δ CRP
14,507 Δ IL-6, Δ CRP
14,758 Δ IL-6, Δ CRP
27,788 Δ IL-6, Δ CRP
39,866 Δ C-peptide iv OGTT, Δ C-peptide total OGTT
56,878 Δ IL-6, Δ CRP, Δ fasting insulin
79,628 –
7,042 Δ CRP, Δ FFA
8,208 Δ triglycerides, Δ cholesterol
20,990 Δ IL-6, Δ CRP
21,086 Δ IL-6, Δ CRP, Δ fasting insulin, Δ iv insulin, Δ 120 min plasma glucose
21,278 Δ IL-6, Δ CRP, Δ fasting insulin
28,601 Δ IL-6, Δ CRP
Significant correlations at baseline
5,898 FFA, HDL, CRP
6,663 –
8,741 FFA, triglycerides
50,123 LDL, triglycerides, cholesterol, blood glucose
Table 4 Correlation of peak
data to clinical data
Table 3 Candidate biomarkers of clinical response to the treatment
Peak (Da) Protein identity Level in responder
vs. non responder
p value for treated
(n=34, Mann- Whitney)
ROC p value for treated
(n=34, permutation test)
5,898 Unknown High 0.035 0.718 0.023
6,663 Unknown Low 0.018 0.750 0.017
8,741 Unknown Low 0.055 0.700 0.044
50,123 Unknown High 0.065 0.692 0.035
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Fig. 1 The top spectra in a–e
are derived from albumin-
depleted serum depleted of TTR
(a-c), RBP4 (d) and Tf (e).
Peaks with the masses of
13,752, 13,889, 13,944, 14,089,
14,300, 14,507, 14,758, and
27,788 Da disappeared when
one human reference serum was
depleted of TTR. Protein peaks
with the masses of 21,086 and
21,278 Da disappeared when
one human reference serum was
depleted of RBP4. The peak
with the mass of 79,628 Da
disappeared when one human
reference serum was depleted of
transferrin. The bottom spectra


















































































































Fig. 2 Western blotting
and SELDI analysis of sera
from patients with low,
intermediate and high




pattern found by SELDI
analysis
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revert after insulin treatment and improved metabolic
control [22, 30]. Findings on the relationship between the
level of circulating RBP4 and components of the metabolic
syndrome are conflicting, with some studies reporting no
correlation between RPB4 and insulin resistance [31–33]
and other studies showing that RBP4 levels correlate
positively with insulin resistance in type 2 diabetic subjects
as well as in non-diabetic subjects [34, 35]. Elevated serum
RBP4 has been positively associated with increased BMI,
fasting insulin, waist-to-hip ratio, TG, systolic and diastolic
blood pressure, fasting BG, 2 h post-OGTT glucose
concentration and decreased HDL levels [34–37]. Conversely,
a decreased plasma RBP4 concentration in obese female
children compared with lean controls [32] and no differences
in circulating RBP4 level between obese and lean postmen-
opausal women [31] have been observed. In a recent paper,
RBP4 has been linked to insulin resistance in a non-causal
manner [38]. We found increased serum RBP4 as a
consequence of anakinra treatment, a positive correlation
between changes in serum RBP4 and changes in fasting
insulin and a negative correlation between changes in serum
RBP4 and changes in CRP and IL-6.
The serum level of the 28,601 Da protein increased as
a consequence of anakinra treatment. If the preliminary
identity of the protein is confirmed as modified apo-AI,
our results confirm a negative correlation between apo-
AI and inflammatory markers that is in accordance with
apo-AI having anti-inflammatory properties [39]. If a
modified form of apo-AI possesses the same antiatherogenic
properties as apo-AI, it is possible that the anakinra-induced
increase in the serum level of modified apo-AI may add a
direct, important and unexpected benefit of anakinra treatment
as a protector against cardiovascular disease (CVD).
Serum Tf increased in the anakinra responder group and
is therefore a candidate surrogate biomarker for improved
glycemia. Tf has been shown to be reduced in the acute
phase response as well as in diabetic patients [25] with a
higher risk of developing late complications. The increase
observed in the anakinra responder group is postulated
to be a result of decreased inflammation. The properties
of Tf suggest that an anakinra-induced increase in
serum Tf is associated with improvement of CVD risk
because of increased iron-binding antioxidant capacity
resulting in less iron-induced oxidative stress and lipid
peroxidation.
In conclusion, we found 22 candidate biomarkers and
identified three of them as TTR, RBP4 and Tf. Based on
the mass and Western blot findings, we assigned the
preliminary identification of modified apo-AI to a
28,601 Da protein. Twelve proteins (including increased
serum TTR and Tf) were potentially useful as surrogates for
improved glycemia, six biomarkers (including serum RPB4
and modified apo-AI) increased expression as a consequence
of anakinra treatment and four proteins were candidate
biomarkers for a glycemic response to anakinra treatment.
Furthermore, we found increased RBP4 to be associated with
improved beta cell secretory function and increased TTR,
RBP4 and modified apo-AI to be associated with decreased
inflammation. Apo-AI and Tf are important anti-atherogenic
factors. Taken together, our results suggest that the anakinra-
induced changes in the serum proteome pool are associated
with a decreased CVD risk, reduced inflammation and
improved beta cell secretory function. These hypotheses need
to be tested in prospective studies.
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